Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cenvacibart · REGN-7508

Monoclonal antibody · Inhibitor of coagulation factor XI (F11) · developed by REGENERON PHARMACEUTICALS

Phase 3 Most advanced trial
REGN Developer
1 Registered trials

What is Cenvacibart?

Cenvacibart is an IgG4 human monoclonal antibody that binds the catalytic domain of coagulation factor XI, preventing its activation to FXIa. This inhibits contact activation-initiated blood coagulation and thrombus formation. It is being studied in venous thromboembolism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-7508
Drug type
Monoclonal antibody
Targets
coagulation factor XI (F11)
Mechanism
Inhibitor of coagulation factor XI (F11)
Pathways
contact activation-initiated blood coagulation, thrombus growth and stabilization
Therapy area
Cardiovascular
Developer
REGENERON PHARMACEUTICALS (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
6NM5PD4YTH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07318610 Phase 3 Peripheral Artery Disease (PAD) Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Venous Thromboembolism (VTE)

Other drugs acting on F11

More from REGENERON PHARMACEUTICALS

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Cenvacibart

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.